With more than 2,200 treatments currently under clinical development worldwide, the pipeline of cell and gene therapies (CGT) is expanding at an astonishing rate. The field welcomed a record $23 billion influx of funding in 2021, according to the Alliance for Regenerative Medicine, and is set to boom in the near future. Taiwan is now set to follow Japan in adopting regulations favorable to the CGT industry, but challenges remain regarding the safety and quality of these advanced therapies, as well as their manufacturing and supply.  In a panel discussion of the session “Advances in Cell & Gene Therapy”, experts at Bio Asia 2022 discussed recent advances in CGT as well as the opportunities and challenges of CGT in Taiwan.